CoChat

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Open access

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and refractory B-cell malignancies, but resistance and relapses still occur. Better understanding of mechanisms influencing CAR T-cell cytotoxicity and the potential for modulation using small-molecule drugs could improve current immunotherapies. Here, we systematically investigated druggable mechanisms of CAR T-cell cytotoxicity using >500 small-molecule drugs and genome-scale CRISPR-Cas9 loss-of-function screens. We identified several tyrosine kinase inhibitors that inhibit CAR T-cell cytotoxicity by impairing T-cell signaling transcriptional activity. In contrast, the apoptotic modulator drugs SMAC mimetics sensitized B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma cells to anti-CD19 CAR T cells. CRISPR screens identified death receptor signaling through FADD and TNFRSF10B (TRAIL-R2) as a key mediator of CAR T-cell cytotoxicity and elucidated the RIPK1-dependent mechanism of sensitization by SMAC mimetics. Death receptor expression varied across genetic subtypes of B-cell malignancies, suggesting a link between mechanisms of CAR T-cell cytotoxicity and cancer genetics. These results implicate death receptor signaling as an important mediator of cancer cell sensitivity to CAR T-cell cytotoxicity, with potential for pharmacological targeting to enhance cancer immunotherapy. The screening data provide a resource of immunomodulatory properties of cancer drugs and genetic mechanisms influencing CAR T-cell cytotoxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019002121

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 236

Metadata

Authors
Dufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., Ellonen, P., Steinberger, P., Kankainen, M., Aittokallio, T., Keränen, M. A. I., Korhonen, M., & Mustjoki, S.
Affiliations
  • University of Helsinki (FI)
  • Finnish Red Cross (FI)
  • Medical University of Vienna (AT)
  • University of Eastern Finland (FI)
Corresponding author
  • Keränen, Mikko A. I.
  • Korhonen, Matti
Venue
Blood
Published
2020-02-27
Volume
135
Issue
9
Pages
597-609
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2997152681
Cited by
224
References
66
Citations by year
2026: 14 · 2025: 31 · 2024: 41 · 2023: 32 · 2022: 54 · 2021: 30 · 2020: 21
FWCI
11.16
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Aaltodoc (Aalto University) (submittedVersion, cc-by)
  • UEF eRepo (University of Eastern Finland) (submittedVersion, other-oa)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • Helsingin Yliopisto
  • Finska Läkaresällskapet
  • Incyte
  • Biomedicum Helsinki-säätiö
  • Orionin Tutkimussäätiö
  • Syöpäsäätiö
  • Helsinki Institute of Life Science, Helsingin Yliopisto
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
CAR T-cell therapy, CAR T cell cytotoxicity, CRISPR-Cas9 loss-of-function screen, tyrosine kinase inhibitors, IAP antagonists, death receptor signaling, FADD, DR5, RIPK1, apoptosis, B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, CD19 CAR T cells, cancer immunotherapy
MeSH terms
Receptors, Chimeric Antigen, Cytotoxicity Tests, Immunologic, Cytotoxicity, Immunologic, Drug Screening Assays, Antitumor, Humans, Lymphocyte Activation, T-Lymphocytes, Cytotoxic, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Drug Resistance, Neoplasm, Cell Line, Tumor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Clustered Regularly Interspaced Short Palindromic Repeats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.